699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC)
Jeffrey Clarke(Duke Medical Center), George R. Simon(Ohio Department of Health), Lin Gu(Tsinghua University), Hirva Mamdani(Wayne State University), Edward F. Patz(G1 Therapeutics (United States)), Liz Gottlin(Duke Medical Center), Jeffrey Crawford(Duke Medical Center), James E. Herndon(Duke University), Scott Antonia(Parker Institute for Cancer Immunotherapy), Michael J. Campa(Duke University), Neal Ready(Duke University), Stephen Baleviic(Duke Medical Center), Ryan T. Bushey(Pennsylvania State University), Andrew B. Nixon(Duke University), Thomas E. Stinchcombe(Duke Medical Center)
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Exploring atomic defects in molybdenum disulphide monolayers
|Nature Communications|2015|1.5k
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Matching the kinetics of natural enzymes with a single-atom iron nanozyme
|Nature Catalysis|2021|1.1k